Equities Analysts Offer Predictions for APLS FY2028 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities researchers at Wedbush decreased their FY2028 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a research note issued to investors on Thursday, October 30th. Wedbush analyst L. Chico now forecasts that the company will earn $0.80 per share for the year, down from their previous forecast of $0.92. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals’ FY2029 earnings at $2.03 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Thursday, October 30th. The company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 24.58%. The firm had revenue of $458.58 million for the quarter, compared to analyst estimates of $364.58 million. During the same period last year, the business earned ($0.46) EPS. Apellis Pharmaceuticals’s revenue for the quarter was up 133.0% compared to the same quarter last year.

Several other equities analysts have also issued reports on APLS. Citigroup dropped their price objective on Apellis Pharmaceuticals from $52.00 to $45.00 and set a “buy” rating on the stock in a report on Friday. Bank of America raised their price objective on Apellis Pharmaceuticals from $23.00 to $24.00 and gave the stock a “neutral” rating in a report on Wednesday, July 16th. HC Wainwright dropped their price objective on Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating on the stock in a report on Friday. Royal Bank Of Canada raised their price objective on Apellis Pharmaceuticals from $17.00 to $19.00 and gave the stock a “sector perform” rating in a report on Friday, August 1st. Finally, JPMorgan Chase & Co. raised their price objective on Apellis Pharmaceuticals from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Monday, August 4th. Ten investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $33.50.

Apellis Pharmaceuticals Stock Performance

Shares of APLS stock opened at $21.47 on Monday. The stock’s 50-day moving average is $25.51 and its two-hundred day moving average is $21.74. The firm has a market cap of $2.72 billion, a price-to-earnings ratio of 69.26 and a beta of 0.70. Apellis Pharmaceuticals has a 1 year low of $16.10 and a 1 year high of $35.72. The company has a debt-to-equity ratio of 2.90, a quick ratio of 3.16 and a current ratio of 3.77.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in APLS. GF Fund Management CO. LTD. boosted its holdings in Apellis Pharmaceuticals by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock valued at $70,000 after purchasing an additional 573 shares in the last quarter. Envestnet Asset Management Inc. boosted its holdings in Apellis Pharmaceuticals by 56.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 43,717 shares of the company’s stock valued at $956,000 after purchasing an additional 15,766 shares in the last quarter. Cerity Partners LLC boosted its holdings in Apellis Pharmaceuticals by 16.7% in the 1st quarter. Cerity Partners LLC now owns 54,444 shares of the company’s stock valued at $1,191,000 after purchasing an additional 7,777 shares in the last quarter. Xponance Inc. boosted its holdings in Apellis Pharmaceuticals by 14.4% in the 1st quarter. Xponance Inc. now owns 16,097 shares of the company’s stock valued at $352,000 after purchasing an additional 2,025 shares in the last quarter. Finally, CWM LLC boosted its holdings in Apellis Pharmaceuticals by 120.3% in the 1st quarter. CWM LLC now owns 98,258 shares of the company’s stock valued at $2,149,000 after purchasing an additional 53,663 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Insider Activity

In other news, CEO Cedric Francois sold 49,963 shares of the firm’s stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $28.39, for a total value of $1,418,449.57. Following the completion of the sale, the chief executive officer owned 307,946 shares in the company, valued at approximately $8,742,586.94. This trade represents a 13.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Timothy Eugene Sullivan sold 10,000 shares of the firm’s stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $28.03, for a total transaction of $280,300.00. Following the completion of the sale, the chief financial officer owned 110,936 shares of the company’s stock, valued at $3,109,536.08. This trade represents a 8.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 312,921 shares of company stock worth $8,490,866 over the last quarter. Insiders own 6.80% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).